Related Experiment Video
Updated: Jun 15, 2025
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
The enzyme SMPDL3b in podocytes decouples proteinuria from chronic kidney disease progression in experimental Alport
Alla Mitrofanova1, Antonio M Fontanella1, Judith Molina1
1Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, Miami, Florida, USA; Peggy and Harold Katz Family Drug Discovery Center, University of Miami, Miller School of Medicine, Miami, Florida, USA.
Background:
Chronic kidney disease, including Alport Syndrome, is linked to collagen type IV mutations, lipid dysmetabolism, and altered sphingolipid pathways, with no targeted therapies currently available. Sphingomyelin phosphodiesterase acid-like 3b (SMPDL3b), a key regulator of sphingolipid metabolism and membrane receptor organization in podocytes, may drive disease via ceramide and sphingosine-1-phosphate pathways. This study tested whether altered SMPDL3b expression contributes to glomerular injury and renal decline in Alport Syndrome.
Methods:
Archived Alport Syndrome human biopsies were used for immunohistochemistry and NanoString re-analysis of SMPDL3b. Murine podocytes isolated from mouse models of Alport Syndrome were profiled using Illumina. Mouse models of Alport Syndrome and models with either podocyte-specific deletion or inducible overexpression of Smpdl3b were generated to assess renal function using liquid chromatography-mass spectrometry, matrix-assisted laser desorption ionization-mass spectrometry imaging and atomic force microscopy.
Results:
We found a three-fold increase in SMPDL3b expression in glomeruli, tubules and murine podocytes isolated from Col4a3 knockout mice. Increased SMPDL3b expression occurred in association with alterations affecting kidney sphingolipid metabolism, increased glomerular but not tubular sphingosine-1-phosphate levels and reduced glomerular basement membrane and podocyte stiffness. Podocyte-specific Smpdl3b deletion in Col4a3 knockout mice was sufficient to restore sphingosine-1-phosphate levels, to reduce proteinuria, podocyte foot process effacement, and improve glomerular basement membrane and podocyte stiffness, but not sufficient to protect from kidney failure.
Conclusions:
Our study suggests that SMPDL3b may be a key modulator of proteinuria and podocyte integrity in Alport Syndrome, decoupling proteinuria from kidney failure, and suggests that improvement of glomerular structure and function may not always translate into protection from chronic kidney disease progression.
More Related Videos
09:40Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells
Published on: June 20, 2018
07:35Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
